3
Indication details
- Control Arm
- Single arm (Phase II)
- FDA Therapeutic Indication
- Patients with HCC who have been previously treated with sorafenib
- Tumour Type
-
Gastrointestinal Cancers
- Tumour Sub-type
- Hepatobiliary Cancers - Hepatocellular Carcinoma
- Tumour Stage
- Unresectable or metastatic
- Trial Name
- CheckMate 040
- NCT Number
- NCT01658878
- Trial Phase
- Phase I/II
Approval details
- FDA Approval
- FDA approval March 2020
- EMA Approval
- Not approved by the EMA
Primary Outcome(s)
- Primary Outcome(s)
- ORR/DoR
- Evaluated Outcome
- ORR
- Form(s)
- Form 3
Outcome Data
- ORR
- 32%
- DoR
- >9 months
Adjustments
- QoL Comment
-
Not qualified for an ESMO-MCBS credit
Score (after adjustments)
- Preliminary non-curative score
-
3
- Non-curative score
-
3
- Comment
-
Approval was based on Arm A (4 doses nivolumab 1 mg/kg plus ipilimumab 3 mg/kg Q3W then nivolumab 240 mg Q2W)
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 251
- Scorecard version
- 1
- Issue date
- 23.03.2021
- Last update
- 15.06.2023
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.